MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced that it has begun enrolling in the PRECEDE-HF clinical trial that will evaluate Medtronic’s proprietary Cardiac Compass® and OptiVol® Fluid Status Monitoring features to determine whether cardiac trend data may help physicians prevent heart failure hospitalizations. Cardiac Compass data and OptiVol Fluid Status Monitoring are currently available on some of Medtronic’s newest devices, the Concerto® and InSync Sentry® cardiac resynchronization therapy-defibrillators (CRT-Ds) and Virtuoso® implantable cardioverter-defibrillator (ICD). Device and physiologic trend data can be accessed remotely via the Medtronic CareLink® Network, or during in-office visits for patients with these devices.
